This educational offering will focus on core topics in hematopoietic cell transplantation (HCT) and cellular therapy. The target audience is PGY2 Oncology Pharmacy Residents, but participation is open to all pharmacists or pharmacy trainees practicing or interested in transplantation and cellular therapy.

Join our expert panelists in this roundtable webinar in recognition the inaugural GVHD Day on Friday, February 17, to discuss unmet needs in graft-versus-host disease (GVHD).

Join Dr. Kirk R. Schultz from the University of British Columbia as he discusses new and emerging therapies in cGvHD. In this 20 min. presentation, he focuses on the future directions of treatment for cGvHD, including the idea of synergistic therapy and how biomarkers may be used to personalize therapy.

Join Olaf Penack, MD from the Charité Universitätsmedizin Berlin, Germany as he reviews the management of cGVHD. In this 20 minute presentation, he focuses on prevention strategies for infectious and non-infectious complications of the disease and discusses current gaps that future research may fill.

In this 20 minute module, Dr. Kirsten Williams from Children’s Healthcare of Atlanta reviews the most recent NIH consensus statements on diagnosis, staging, and response scoring of chronic graft-versus-host disease after hematopoietic stem cell transplant. The current focus in this area is early detection. This is a first in a series of three modules addressing unmet needs in chronic graft versus host disease.

ASTCT offers its members the information, tools and forms they need to stay informed and involved in efforts to develop more effective treatments for chronic graft-versus-host disease (chronic GVHD) — an urgent unmet clinical need and the most frequent complication after HCT. This presentation is by Stella K. Kim, M.D., MD Anderson Cancer Center, and Michael R. Robinson, M.D., National Eye Institute, NIH, after the 2014 Consesn Conference on GVHD.

ASTCT offers its members the information, tools and forms they need to stay informed and involved in efforts to develop more effective treatments for chronic graft-versus-host disease (chronic GVHD) — an urgent unmet clinical need and the most frequent complication after HCT. This presentation is by Mark M. Schubert, DDS, MSD, Fred Hutchinson Cancer Research Center, after the 2014 Consesn Conference on GVHD.

ASTCT offers its members the information, tools and forms they need to stay informed and involved in efforts to develop more effective treatments for chronic graft-versus-host disease (chronic GVHD) — an urgent unmet clinical need and the most frequent complication after HCT. This presentation is by Steven Z. Pavletic, M.D., National Cancer Institute, NIH, after the 2014 Consesn Conference on GVHD.